The researchers found a third shot had a strong booster effect
Vials containing CoronaVac, Sinovac Biotech’s vaccine. Picture: REUTERS/AMANDA PEROBELLIAntibodies triggered by Sinovac Biotech’s Covid-19 vaccine declined below a key threshold from about six months after a second dose for most recipients, but a third shot had a strong booster effect, a laboratory study showed.
Researchers said it was unclear how the decrease in antibodies would affect the shot’s effectiveness, since scientists have yet to figure out precisely the threshold of antibody levels for a vaccine to be able to prevent the disease. As of end-June, Sinovac has delivered more than 1-billion doses of the vaccine, a major vaccination tool in China, Brazil, Indonesia and Chile.
She said the immunisation advisory board recommends a booster vaccination 12 months after the second dose.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study shows antibodies from Sinovac vaccine fade after six monthsThe researchers found a third shot had a strong booster effect
Read more »
CSIR study uncovers shocking food wastage in SAA new study shows that 45% of the available food supply in SA is wasted, pointing to high levels of inefficiency in the food value chain while there is increasing food insecurity in the country.
Read more »
Study shows antibodies from Sinovac vaccine fade after six monthsThe researchers found a third shot had a strong booster effect
Read more »
Joe Phaahla urged to get backup vaccines for Pfizer and J&JEffort must be made to secure AstraZeneca and Sinovac Biotech vaccines in the event of a potential shortage of the Pfizer and J&J doses
Read more »
COVID-19 | China approves first mixed-vaccine trial as Delta spreadsThe trial will test the efficacy of combining an 'inactivated' vaccine made by China's Sinovac with a DNA-based one developed by US pharmaceutical company Inovio.
Read more »
Exxaro expects to double profitsThe company forecasts headline earnings of between R26.32 and R27.92 a share for the six months to end June.
Read more »